AI is speeding up drug discovery by predicting molecular interactions, identifying potential compounds, and simulating protein folding. Techniques like deep learning models (e.g., AlphaFold) help researchers identify viable treatment candidates in months rather than years.
This post covers pharma adoption of AI in drug screening, partnerships with biotech startups, and the role of synthetic data in privacy-sensitive environments. It also discusses regulatory hurdles and clinical validation steps. For healthcare innovation, AI is not just a tool—it’s a time accelerator.
